The company posted $563.4 million in revenues for the quarter ended Oct. 4, up from $542.0 million for the same period a year ago.
Fitch upgraded PerkinElmer's issuer default rating to BBB and cited the firm's improved operating profit and the potential for M&A.
Overall, analyst Bryan Brokmeier said he is bullish on the space in spite of uncertainty in the general global markets.
In a regulatory document, the company said the layoffs resulted from a restructuring plan to "emphasize growth initiatives."
The company reported $563.9 million in revenues for the quarter, up from $556.2 million for the same period a year ago.
The partners will provide drug discovery services, expertise, and infrastructure in a new AMRI center located in the Buffalo Medical Innovation and Commercialization Hub.
Revenues for the quarter were down around one percent compared to last year. On a constant-currency basis, though, its sales were up 5 percent.
The deal provides PerkinElmer access to Applied BioCode's Barcoded Magnetic Bead technology, including the BioCode MDx 3000 instrument.
The firm also said that currency translation had a negative effect of $53 million last year.
PerkinElmer's liquid and gas chromatography portfolio will be standardized on Waters' Empower Software.
NPR reports that many USDA researchers working at the two agencies that are relocating to the Kansas City area are declining to go.
Genetic genealogy has helped exonerate a man who has been jailed for 20 years, Agence France Presse reports.
A new report says genetically modified food might be necessary to be able to feed a planet of nearly 10 billion people, Bloomberg says.
In Nature this week: new RNA editing approach called LEAPER, draft assembly of Musa balbisiana banana genome, and more.